Welcome to the Precipio Shareholder -- Second Quarter 2022 Shareholder Update Conference Call. (Operator Instructions) Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon our current expectations, forecasts and assumptions, and are subject to significant risks and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue or the negative of these terms or other words or terms of similar meaning. Risks and uncertainties that could cause our actual results to differ materially from those set forth in any forward-looking statements include, but are not limited to, the matters listed under Risk Factors in our annual report on Form 10-K for the year ended December 31, 2020, which is filed with the Securities and Exchange Commission as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available on www.sec.gov. Statements and information, including forward-looking statements, speak only to the date they are provided, unless earlier date is indicated. And we do not undertake any obligation to publicly update any statements or information, including forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Now let me hand the call over to Ilan Danieli, Precipio's CEO.

Thank you, Anthony. Hello and good afternoon, everyone, and thanks for joining our 2022 second quarter shareholder update call. Thanks also for those who've sent in your questions. Hopefully, we'll be able to address them in today's call. I realize this is an August summer afternoon, and if you are not , in the Northeast, it's a beautiful one. So I'll do my best to keep this brief. Today, I'd like to expand on a few of the recent news items we released over the past few months and give you a little more color into what we've been working on and our plans going forward. As you can see from the recent activity, as our pathology services division continues to grow, management's focus is on the product division. And I'd like to discuss 3 aspects of this division and share with you the work we've been doing. The first is distribution partnerships. The second is our product portfolio. And the third is team. Let's begin with distribution partners. As we said all along, our intent is not to build our own sales force to sell HemeScreen and other products, rather to leverage distributors who have already -- who already have existing sales teams. The challenges of finding and hiring a team, the time line until they become productive, and of course, the costs simply don't align with our company goals. Particularly post COVID where access to customers and recovery is harder, partnering with teams with preexisting relationships is critical to knowing who the right decision makers are within that (inaudible) organization, gaining quick access to them and ultimately making the sale. We began our partnership with AON Solutions as distributor of (inaudible), which help us obtain our very first customers. That partnership continues to grow. Over the next few…

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.